Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Christmas oncology roundup
The holiday period included Genmab’s discontinuation of acasunlimab.
Astra enters the pan-KRAS game
A deal with Jacobio is worth $100m up front.
The conjugate enthusiasm bypasses Mythic
The private ADC company is being wound down.
Crescent moves to close the bispecific gap
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
AnaptysBio and GSK fall out again
Five years after settling, GSK is again accused of breaching the Jemperli deal.
